SuanNutra's IFF Deal: Forging a Global Leader in Natural Ingredients

MADRID, Spain – July 20, 2026 – In a move that signals a significant consolidation within the global ingredients market, SuanNutra, backed by private equity firm Carbyne Equity Partners, has announced its agreement to acquire a portfolio of specialty natural ingredients businesses from International Flavors & Fragrances (IFF). While M&A activity is a constant hum in the background of global business, this transaction is a clear signal of where durable value is being created. It is a calculated play for dominance in a sector being fundamentally reshaped by consumer demand for transparency, science, and nature.

The deal, expected to close by the end of 2026 pending regulatory approvals, will merge IFF's divested assets—which generated approximately $170 million in revenue last year—into SuanNutra's existing operations. This is not a simple bolt-on acquisition; it is a transformational step designed to create a new category leader with the scale, scientific credibility, and global footprint necessary to win in the 21st-century wellness economy.

A Strategic Play in a Shifting Market

At the heart of this transaction is a powerful secular trend: the accelerating consumer migration from synthetic additives to natural, clean-label ingredients. For decades, the food and supplement industries relied on artificial colors, flavors, and preservatives. Today, that paradigm is crumbling under the weight of consumer demand for authenticity and scientifically validated wellness. SuanNutra’s acquisition is a direct response to this tectonic shift.

The incoming portfolio from IFF includes botanical extracts, fermented vitamins and minerals, and a suite of plant-derived natural colors, antioxidants, and flavors. These are not commodity products; they are high-value, functional ingredients that enable food and nutraceutical manufacturers to meet the clean-label demands of modern consumers. As SuanNutra's Non-Executive Chairman, Yoni Glickman, noted, the industry is moving decisively toward “proven actives with the science to stand behind them.”

This acquisition places SuanNutra at the epicenter of that movement. The company's 'Visible Health' strategy—which centers on clinically backed ingredients that deliver wellness benefits consumers can see and feel—is significantly bolstered by the deal. It's a move from abstract health claims to measurable, tangible outcomes, a transition that builds consumer trust and brand loyalty. The combination creates a powerhouse in both nutraceuticals and food enhancement, positioning the enlarged group as a critical partner for brands navigating this complex transition.

Forging a Resilient Global Platform

Beyond market trends, the structure of this deal reveals a focus on building a resilient, vertically integrated operation. The combined entity will boast a manufacturing footprint that spans the globe, with botanical extraction facilities in Spain, Slovenia, and Peru, and advanced fermentation operations in the United States. This control over the supply chain, from source to final ingredient, is a powerful competitive advantage. It ensures quality, traceability, and a stable supply in an increasingly volatile world.

Upon completion, the merged group will employ around 700 people and serve over 1,200 customers in more than 60 countries, giving it genuine global scale. For IFF, the divestiture is equally strategic. It represents another step in a multi-year effort to streamline its portfolio and concentrate on its core, high-innovation businesses in Taste, Scent, and Health & Biosciences. This is not a case of a company shedding underperforming assets, but rather a deliberate refocusing that allows a specialized player like SuanNutra to unlock the full potential of these natural ingredient lines.

Anthony Weston, Group CEO of SuanNutra, emphasized the human element of the merger, stating, "The engaged, experienced people in these businesses know the products and customers deeply, and that expertise is central to everything we aspire to achieve." This acknowledgment is crucial. In any large-scale integration, the retention of institutional knowledge and technical expertise is a primary determinant of long-term success. The vision is to build a stronger, more capable partner for customers, leveraging a broad natural portfolio and deep scientific expertise.

The Private Equity Playbook in Action

Observing this transaction through the lens of its financial architects, Carbyne Equity Partners, reveals a classic and effective private equity strategy. Carbyne, which acquired SuanNutra in December 2025 to serve as a standalone platform, is executing a 'buy and build' strategy. This involves acquiring a strong foundational company and then aggressively scaling it through strategic M&A and organic growth.

As Markus Petersen, Managing Partner of Carbyne, explained, "This merger creates a botanical-based ingredients group of genuine scale and scientific credibility, and we are pleased to back the team in building it." The firm’s investment thesis is clearly centered on the resilience and high-growth potential of the specialty ingredients sector. Mai Karas, Investment Director at Carbyne, reinforced this, concluding, "Specialty ingredients are at the heart of Carbyne's investment strategy."

This is not a short-term financial flip. It is a long-term play to construct a market leader in a non-cyclical industry driven by deep-seated consumer trends. Private equity provides the capital and strategic oversight to pursue transformational acquisitions that might be out of reach for a standalone company, accelerating its journey to market leadership. Carbyne is betting that by combining SuanNutra's focus with IFF's established assets, it can create a whole far greater than the sum of its parts.

The Path Forward: Integration and Innovation

With the agreement signed, the focus now shifts to execution. The transaction's closure by year-end is contingent on navigating the standard regulatory hurdles, which will likely include antitrust reviews in key jurisdictions. However, the true test of this strategy's permanence will be in the integration of the two organizations. Merging distinct corporate cultures, supply chains, and R&D pipelines across multiple continents is a formidable challenge.

SuanNutra's leadership has committed to a seamless transition for customers and continued investment in innovation across the enlarged group. This commitment will be vital. The long-term value of this deal will not be realized on the day the papers are signed, but in the months and years that follow, as the combined entity leverages its new scale and scientific depth to out-innovate competitors. The promise is to build, grow, and transform the group into an indispensable partner in the global shift toward natural, science-backed wellness.